Fosun International

What Fosun International does

Fosun International Limited (复星国际有限公司) is a Shanghai-headquartered, Hong Kong-listed (00656.HK) global conglomerate founded in 1992 by Guo Guangchang. The company operates four core business segments: Health (biopharmaceuticals, medical devices, diagnostics, and healthcare services through Fosun Pharma, Henlius, and Gland Pharma); Happiness (tourism, luxury retail, and cultural consumption through Club Med, Atlantis Sanya, Yuyuan, and Lanvin Group); Wealth (insurance and asset management through Fidelidade, Peak Reinsurance, and Fosun Prudential Life); and Intelligent Manufacturing (strategic resources, functional materials, and intelligent manufacturing through Hainan Mining and other subsidiaries). Fosun reports operations across more than 40 countries and regions with overseas revenue accounting for 54.7% of the FY2025 total of RMB 173.43 billion.

The company's core products include innovative biopharmaceuticals (HANSIZHUANG anti-PD-1 monoclonal antibody approved in 40+ countries, Yi Kai Da CAR-T cell therapy, Trastuzumab biosimilar, Luvometinib Class 1 new drug, and the HLX43 PD-L1 ADC candidate in international Phase III trials); tourism operations (67 Club Med resorts globally and the Atlantis Sanya resort complex); insurance products through Fidelidade (Portugal's largest insurer with 28.1% market share) and Peak Reinsurance (USD 2.2 billion gross written premiums in 2025); and consumer brands through Yuyuan's 3,963 jewelry and fashion stores. Underlying technology platforms include the PharmAID pharmaceutical R&D intelligence platform (reported ~50% efficiency improvement in drug development intelligence extraction), AI G.O. guest service system for tourism, and digital insurance platforms supporting Fidelidade's digital user base approaching 22% of Portugal's population. The company holds 1,220 authorized invention patents.

Fosun's business model combines B2C distribution (resort operations, consumer retail, insurance policyholders) with B2B partnerships and licensing (pharmaceutical licensing deals including Pfizer at over USD 2 billion and Clavis Bio at up to USD 7.25 billion, plus reinsurance underwriting). Revenue streams span subscription/recurring (insurance, healthcare services, resort operations) and one-time licensing (pharmaceutical IP licensing, asset sales). The FC2M (Family-to-Manufacturer) ecosystem strategy attempts to cross-sell across health, happiness, and wealth segments to global family customers. The group is undergoing active portfolio rationalization, including privatizations of Fosun Tourism and Henlius (combined ~HK$7.7 billion in early 2025), planned IPOs for Club Med and Fidelidade, and partial divestitures including Luz Saúde (40% to Macquarie for ~USD 364 million) and minority Peak Re stakes to KKR and Quadrantis. Despite RMB 173.43 billion in FY2025 revenue, the group reported a RMB 23.4 billion net loss due to asset impairments in real estate and non-core assets, indicating the portfolio is being actively optimized around higher-return core subsidiaries.

Name

Fosun International

Legal name

Fosun International Limited

Website

https://fosun.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fosun International is a Shanghai-headquartered, Hong Kong-listed global conglomerate founded in 1992 operating across healthcare, tourism, insurance, and intelligent manufacturing segments, with businesses in more than 40 countries serving global family customers through its FC2M ecosystem model.

Ownership category

akta.pro rank

Product category

Global Diversified Conglomerate

NAICS

Direct Life, Health, and Medical Insurance Carriers (52411), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Health and Welfare Funds (525120)

SIC

Pharmaceutical Preparations (2834), Insurance Agents, Brokers & Service (6411)

akta.pro primary industry

Manufacturing, MSAT & Operations Staffing (API/Biologics/Cell & Gene) (HLAGAOAL)

akta.pro secondary industry

Claims Management & Digital FNOL Platforms (FSAGAGAC)

Keywords

• Diversified consumer conglomerate
• Pharmaceutical and healthcare
• Insurance and reinsurance
• Global tourism and hospitality
• Smart manufacturing and mining

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Health (Pharmaceuticals & Healthcare): Includes biopharmaceuticals, medical devices, diagnostics, and health services through subsidiaries including Fosun Pharma and Henlius
2. Happiness (Tourism & Consumer): Global tourism operations including Club Med resorts, Atlantis Sanya, and consumer brands through Fosun Tourism Culture and Yuyuan
3. Wealth (Insurance & Asset Management): Insurance operations through Fosun Portugal Insurance (Fidelidade), Peak Reinsurance, and asset management businesses
4. Smart Manufacturing: Strategic resources, functional materials, and intelligent manufacturing through subsidiaries including Hainan Mining

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Fosun International is a global innovation-driven family consumer industry group operating across four core segments: Health (biopharmaceuticals, medical devices, diagnostics, healthcare services through Fosun Pharma and Henlius), Happiness (tourism and consumer brands through Club Med, Atlantis Sanya, and Yuyuan), Wealth (insurance and asset management through Fidelidade and Peak Reinsurance), and Smart Manufacturing (strategic resources and functional materials through Hainan Mining). The company offers integrated products and services spanning 40+ countries, with key offerings including innovative oncology drugs, premium resort experiences, insurance policies, and industrial resources.

Product overview

Fosun International is an innovation-driven global family consumer industry group with a diversified portfolio of four core business segments: Health (biopharmaceuticals, medical devices, diagnostics, healthcare services), Happy (tourism, luxury retail, cultural experiences), Rich (insurance, investment management, property), and Intelligent Manufacturing (resources, smart manufacturing). The company operates multiple listed subsidiaries including Fosun Pharma (600196.SH, 02196.HK), Henlius (2696.HK), Fosun Tourism (delisted from HKEX in March 2025), Yuyuan (600655.SH), Hainan Mining (601969.SH), and Lanvin Group (LANV, NYSE). Key products include innovative drugs like HANSIZHUANG (anti-PD-1 antibody),奕凯达 (CAR-T therapy), 汉曲优 (biosimilar), and HLX43 (PD-L1 ADC); tourism brands like Club Med (67 resorts globally), Atlantis Sanya, and Yuyuan Bazaar; insurance operations through Fidelidade and Peak Re; and technology platforms like PharmAID and AI G.O. for operational efficiency.

Differentiator

Problem solved

Functional benefit

Brands

• FC2M: Customer-to-Maker ecosystem connecting family consumption needs with industrial capabilities
• FES (Fosun Entrepreneurship/Ecosystem System)
• Create IMPACT

Products and services

• Fosun Pharma (复星医药) Innovation-driven global pharmaceutical and healthcare industry group operating pharmaceutical, medical devices, medical diagnosis, and healthcare services businesses. Generated RMB 41.66 billion revenue in 2025 with RMB 98.93 billion in innovative drug revenue.
• HANSIZHUANG / Serplulimab (European name: Hetronifly) Anti-PD-1 monoclonal antibody approved in over 40 countries and regions. First anti-PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in EU. Global sales reached RMB 14.93 billion in 2025.
• Yi Kai Da / Axicabtagene Ciloleucel (CAR-T) CAR-T cell therapy product for treatment of relapsed/refractory large B-cell lymphoma. Included in first commercial insurance innovative drug directory to improve patient accessibility.
• Han Quyou / Trastuzumab (European name: Zercepac) Biosimilar monoclonal antibody for HER2-positive breast and gastric cancer treatment. Approved in over 40 countries and regions globally.
• Fudanning / FUMAINING CDK4/6 Inhibitor CDK4/6 inhibitor with 2 indications approved for breast cancer treatment, providing new therapeutic options for patients.
• Famuning (复迈宁) MEK 1/2 Inhibitor MEK 1/2 inhibitor approved for adult LCH and histiocytic tumors, pediatric NF1 plexiform neurofibroma, and pediatric LCH. Only domestic drug covering both adult LCH and pediatric NF1 dual indications.
• HLX43 PD-L1 ADC Potential best-in-class broad-spectrum anti-tumor PD-L1 ADC showing efficient, low-toxicity advantages in non-small cell lung cancer, gynecological oncology, and esophageal squamous cell carcinoma.
• Club Med / Fosun Tourism (复星旅文) Global comprehensive tourism and leisure resort group operating 67 Club Med resorts across over 40 countries and regions. Generated RMB 17.97 billion revenue in 2025 with 75.8% average occupancy rate and 8.6 million guests served annually.
• Atlantis Sanya (三亚亚特兰蒂斯) Luxury resort complex in Hainan with water park, aquarium, and hotel facilities. Plan to spin off and list on Shanghai Stock Exchange as Chinese commercial property REIT.
• Yuyuan Inc. (豫园股份) Leading Chinese family consumption group with 19 time-honored brands and 8 intangible cultural heritage projects. Generated RMB 36.4 billion revenue with 3,963 jewelry and fashion stores. Brands include Laomiao gold, Shede spirits, Songhelou restaurant.
• Fidelidade (复星葡萄牙保险) Portugal's leading insurance company with 28.1% market share. Gross written premiums EUR 6.53 billion in 2025 with net profit EUR 201 million, up 15.8%. International business accounts for over 30% of combined business scale. A-level S&P credit rating assigned July 2025.
• Peak Reinsurance (鼎睿再保险) Hong Kong-based reinsurance company with gross written premiums of USD 2.2 billion in 2025, up 25%. Net profit after tax USD 189.5 million.
• Hainan Mining (海南矿业) Resources and energy company with iron ore, oil and gas, and lithium operations. Mali Bougouni lithium mine produced 45,000 tons of lithium concentrate in 2025, with first 30,000 tons arriving at Yangpu Port in January 2026.
• Henlius (复宏汉霖) Innovation-driven biopharmaceutical company generating RMB 6.667 billion revenue in 2025 with RMB 827 million net profit, achieving three consecutive years of revenue and profit growth.
• Lanvin Group (复朗集团) Global luxury fashion group listed on NYSE (LANV) operating Lanvin, Sergio Rossi, and other fashion brands.
• Fosun Prudential Life (复星保德信人寿) Life insurance company with scale premiums of RMB 13.28 billion in 2025, up 41.6%, and net profit of RMB 650 million, up 492% year-over-year.
• Artesunate for Injection WHO-recommended first-line treatment for severe malaria. Has saved over 88 million severe malaria patients globally with over 440 million vials supplied worldwide as of end-2025.

Quantifiable outcome

• Over 88 million severe malaria patients saved globally with Artesunate for injection
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

Six partnerships are on record, tiered subsidiary, strategic and major.

• PAREF (subsidiary)subsidiaryOthers · 16 June 2026Takuya Yamada, Global COO of Fosun Hive Overseas, appointed as interim Chairman and CEO of PAREF (real estate investment company). PAREF manages over €3 billion in AUM across France, Germany, Italy, and Switzerland.
• EHL AlliancestrategicStrategic or Co-development Partner · 20 April 2026Train of Glamour (Fosun Infrastructure Group) joined EHL Alliance as first Chinese member. Partnership includes five strategic initiatives for co-developing China's first luxury rail service standards and talent exchange programs.
• MSCI (for ESG Rating)strategicOthers · 26 March 2026MSCI upgraded Fosun's ESG rating from AA to AAA, recognizing strong performance across environmental, social, and governance dimensions, particularly in responsible investment, business ethics, and clean technology opportunities.
• S&P Global (for Sustainability Assessment)strategicOthers · 26 March 2026S&P Global recognized Fosun in the Sustainability Yearbook 2026 with CSA score of 73, ranking in global industry top 7%. Part of ongoing ESG recognition ecosystem.
• PfizermajorStrategic or Co-development Partner · 11 November 2025Major global pharmaceutical licensing agreements including deals with Pfizer (over USD 2 billion) for GLP-1 target YP05002 global license.
• Clavis BiomajorStrategic or Co-development Partner · 11 November 2025Global pharmaceutical licensing agreements including deal with Clavis Bio with potential value up to USD 7.25 billion.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• CK Hutchison Holdings: Hong Kong-listed conglomerate with diversified global operations in healthcare, infrastructure, telecommunications, and retail. Directly comparable to Fosun as a Chinese-origin, Hong Kong-listed diversified holding pursuing global M&A and operating in similar healthcare and consumer segments.
• Jardine Matheson Holdings: Asia-based diversified holding company with healthcare, insurance, and consumer operations across Asia. Comparable to Fosun in its conglomerate structure, Asia-headquartered, long-term family-controlled governance, and global portfolio of operating businesses.
• CITIC Limited: Chinese state-linked diversified conglomerate operating in financial services, resources, real estate, manufacturing, and consumer. Closely comparable to Fosun as a mainland-China-rooted conglomerate with mixed ownership structure, large balance sheet, and exposure to global capital markets.
• Legend Holdings: Chinese diversified holding company (parent of Lenovo) with strategic investment operations across IT, financial services, and consumer. Comparable to Fosun in scale, Chinese origin, public listing, and strategy of building a multi-sector global portfolio through acquisitions.

Broad incumbents

• Berkshire Hathaway: Largest global diversified holding company with insurance (GEICO, reinsurance), healthcare, and consumer operations. Comparable to Fosun as a large, decentralized, multi-segment conglomerate with a major insurance engine and selective global capital deployment, though much larger and US-based.
• China Resources (Holdings): Hong Kong-listed Chinese state-owned conglomerate with healthcare, consumer (beer, retail), real estate, and financial services businesses. Comparable in scale and sector mix to Fosun, especially on the consumer and healthcare dimensions, though state-owned rather than privately controlled.
• Swire Pacific: Hong Kong-listed conglomerate with divisions in real estate, aviation, healthcare (trading and industrial), and marine services. Comparable to Fosun as a long-established Asia-rooted holding company pursuing global operations across cyclical and defensive sectors.
• AIA Group: Hong Kong-listed pan-Asian life insurance leader with operations across 18 Asia-Pacific markets. Comparable to Fosun's insurance arm (Fidelidade, Peak Re, Fosun Prudential Life) in product mix and Hong Kong listing, though much larger and more focused on life and health insurance.
• Samsung C&T Corporation: Korean conglomerate with construction, trading, fashion, and bio-pharma operations including Samsung Biologics. Comparable to Fosun as a diversified Asia-headquartered group with a major pharmaceutical and biologics growth engine, plus consumer and real estate operations.

Regional players

• Hengan International: Leading Chinese consumer products group listed in Hong Kong, focused on hygiene and consumer goods. Partially comparable to Fosun's Yuyuan consumer segment in terms of Hong Kong listing and Chinese consumer brand portfolio, though far more focused and not a conglomerate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fosun-international

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries16 records

Funding overview

Funding rounds4 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments122 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fosun International